Ernest Hawk

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint The Translational Research Working Group developmental pathway for lifestyle alterations
    Ernest T Hawk
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5707-13. 2008
  2. doi request reprint The Translational Research Working Group developmental pathways: introduction and overview
    Ernest T Hawk
    Office of Centers, Training, and Resources, National Cancer Institute, Rockville, Maryland, USA
    Clin Cancer Res 14:5664-71. 2008
  3. pmc Translational Research Working Group developmental pathway for biospecimen-based assessment modalities
    Sudhir Srivastava
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5672-7. 2008
  4. ncbi request reprint Aspirin: anticolorectal adenocarcinoma activity in the adjuvant arena?
    Ernest Hawk
    University of Texas MD Anderson Cancer Center, Division of Cancer Prevention and Population Sciences, Houston, TX 77030 1439, USA
    Future Oncol 6:197-200. 2010
  5. pmc MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma
    Xifeng Wu
    Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:196-205. 2013
  6. ncbi request reprint What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment
    Ernest Hawk
    Office of Centers, Training, and Resources, National Cancer Institute OD, Bethesda, MD, USA
    Semin Oncol 33:S6-9. 2006
  7. doi request reprint Cancer chemoprevention: successes and failures
    Sherri L Patterson
    Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Chem 59:94-101. 2013
  8. pmc Biomarkers, bundled payments, and colorectal cancer care
    William Ross
    Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Genes Cancer 3:16-22. 2012
  9. doi request reprint Chemoprevention--history and general principles
    Xiangwei Wu
    The University of Texas, M D Anderson Cancer Center, Department of Clinical Cancer Prevention, Houston, TX 77030, USA
    Best Pract Res Clin Gastroenterol 25:445-59. 2011
  10. doi request reprint GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes
    Jingyao Dai
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 33:1327-31. 2012

Collaborators

Detail Information

Publications24

  1. doi request reprint The Translational Research Working Group developmental pathway for lifestyle alterations
    Ernest T Hawk
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5707-13. 2008
    ..This article discusses key issues associated with the development of lifestyle alterations in light of the pathway...
  2. doi request reprint The Translational Research Working Group developmental pathways: introduction and overview
    Ernest T Hawk
    Office of Centers, Training, and Resources, National Cancer Institute, Rockville, Maryland, USA
    Clin Cancer Res 14:5664-71. 2008
    ..Further development of the pathways is encouraged, as is application of the pathway concept to translational research on other diseases...
  3. pmc Translational Research Working Group developmental pathway for biospecimen-based assessment modalities
    Sudhir Srivastava
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5672-7. 2008
    ..This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway...
  4. ncbi request reprint Aspirin: anticolorectal adenocarcinoma activity in the adjuvant arena?
    Ernest Hawk
    University of Texas MD Anderson Cancer Center, Division of Cancer Prevention and Population Sciences, Houston, TX 77030 1439, USA
    Future Oncol 6:197-200. 2010
    ....
  5. pmc MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma
    Xifeng Wu
    Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:196-205. 2013
    ....
  6. ncbi request reprint What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment
    Ernest Hawk
    Office of Centers, Training, and Resources, National Cancer Institute OD, Bethesda, MD, USA
    Semin Oncol 33:S6-9. 2006
    ....
  7. doi request reprint Cancer chemoprevention: successes and failures
    Sherri L Patterson
    Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Chem 59:94-101. 2013
    ..medilexicon.com/drugs-list/cancer.php). Just 13 agents have been approved, however, for treating precancerous lesions or for reducing risk...
  8. pmc Biomarkers, bundled payments, and colorectal cancer care
    William Ross
    Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Genes Cancer 3:16-22. 2012
    ..This promising scenario is still in the future, but progress is being made, and the shape of things to come for cancer care in the age of genomics is becoming clearer...
  9. doi request reprint Chemoprevention--history and general principles
    Xiangwei Wu
    The University of Texas, M D Anderson Cancer Center, Department of Clinical Cancer Prevention, Houston, TX 77030, USA
    Best Pract Res Clin Gastroenterol 25:445-59. 2011
    ..In less than four decades, cancer chemoprevention has transformed from a concept to an achievable reality...
  10. doi request reprint GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes
    Jingyao Dai
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 33:1327-31. 2012
    ..Our results suggest that cancer susceptibility loci may also affect the prognosis of CRC patients receiving fluorouracil-based adjuvant chemotherapy...
  11. ncbi request reprint Cancer prevention and the American Society of Clinical Oncology
    Scott M Lippman
    The University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 22:3848-51. 2004
  12. ncbi request reprint Celecoxib treatment alters the gene expression profile of normal colonic mucosa
    Oleg K Glebov
    Genetics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 15:1382-91. 2006
    ....
  13. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  14. ncbi request reprint Do statins prevent cancer?
    Ernest T Hawk
    Office of Centers, Training and Resources at the National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:478-9. 2006
  15. ncbi request reprint COX-2 in cancer--a player that's defining the rules
    Ernest T Hawk
    J Natl Cancer Inst 94:545-6. 2002
  16. ncbi request reprint Epidemiology and prevention of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Surg Clin North Am 82:905-41. 2002
    ..The challenges and rewards of participation in chemoprevention research--both as patients and health care providers-have never been greater...
  17. ncbi request reprint Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
    Mutat Res 523:137-44. 2003
    ..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality...
  18. ncbi request reprint Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Prog Exp Tumor Res 37:210-42. 2003
  19. ncbi request reprint Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers
    Gary J Kelloff
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 12:593-6. 2003
  20. ncbi request reprint Development of COX inhibitors in cancer prevention and therapy
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892 7317, USA
    Am J Clin Oncol 26:S48-57. 2003
    ..Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits...
  21. ncbi request reprint Frontiers in cancer prevention research
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 63:5649-55. 2003
  22. ncbi request reprint Cyclooxygenase inhibition in cancer prevention and treatment
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Expert Opin Pharmacother 4:2193-204. 2003
    ..A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented...
  23. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  24. ncbi request reprint The role of cyclooxygenase inhibitors in cancer prevention
    William F Anderson
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Curr Pharm Des 8:1035-62. 2002
    ..Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention...